BamSEC and AlphaSense Join Forces
Learn More

Elevation Oncology Inc.

NASDAQ: ELEV    
Share price (12/20/24): $0.58    
Market cap (12/20/24): $34.3 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 9 pages This Change in Control and Severance Agreement (The “Agreement”) Is Entered Into by and Between [Name] (The “Executive”) and Elevation Oncology, Inc., a Delaware Corporation (The “Company”), Effective as of [Date] (The “Effective Date”). 1.qualifying Termination. if the Executive Is Subject to a Qualifying Termination, Then, Subject to Sections 3, 8, and 9 Below, the Executive Will Be Entitled to the Following Benefits
12/34/56
EX-10.1
from 10-Q 24 pages Certain Confidental Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Elevation Oncology, Inc. if Publicly Disclosed
12/34/56
EX-10.2
from 10-Q 4 pages ​ July 12, 2023
12/34/56
EX-10.1
from 10-Q 4 pages ​ July 12, 2023
12/34/56
EX-10.1
from 10-Q 6 pages Certain Identified Information Has Been Excluded From This Exhibit Because Such Information Both (I) Is Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed
12/34/56
EX-10.10
from 10-K 5 pages David Dornan, PH.D. [****] [****] [****] Re: Employment Agreement Dear David: On Behalf of Elevation Oncology, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.2
from 10-Q 47 pages License Agreement
12/34/56
EX-10.1
from 10-Q 76 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Elevation Oncology, Inc. if Publicly Disclosed
12/34/56
EX-10.11
from 10-K 8 pages Valerie Malyvanh Jansen, MD, Phd 149 Burberry Glen Blvd Nolensville, Tn 37135 Re: Executive Employment Agreement Dear Valerie: On Behalf of Elevation Oncology, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.11
from S-1/A 29 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Elevation Oncology, Inc. if Publicly Disclosed. Collaboration Agreement
12/34/56
EX-10.10
from S-1/A 14 pages Joseph J. Ferra, Jr. [*****] [*****] [*****] Re: Executive Employment Agreement Dear Joe: On Behalf of Elevation Oncology, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.9
from S-1/A 21 pages Shawn M. Leland, Pharmd, Rph [*****] [*****] Re: Executive Employment Agreement Dear Shawn: On Behalf of 14ner Oncology, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.4
from S-1/A 13 pages Elevation Oncology, Inc. 2021 Employee Stock Purchase Plan
12/34/56
EX-10.3
from S-1/A 65 pages Elevation Oncology, Inc. 2021 Equity Incentive Plan
12/34/56
EX-10.1
from S-1/A 12 pages Indemnity Agreement
12/34/56
EX-10.10
from S-1/A 29 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Elevation Oncology, Inc. if Publicly Disclosed. Collaboration Agreement
12/34/56
EX-10.8
from S-1 3 pages [Name] [Address] [Address] Re: Initial Public Offering Participation Rights 1. Initial Public Offering Participation Rights
12/34/56
EX-10.7
from S-1 39 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Elevation Oncology, Inc. if Publicly Disclosed. Commercial License Agreement Entered Into With Merrimack Pharmaceuticals, Inc. Confidential Background Confidential Agreement
12/34/56
EX-10.6
from S-1 75 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Elevation Oncology, Inc. if Publicly Disclosed. Amended and Restated Collaboration Agreement
12/34/56
EX-10.5
from S-1 55 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Elevation Oncology, Inc. if Publicly Disclosed
12/34/56